| Breast cancer | Prostate cancer | LAM | |
| Host factors | |||
| Younger age | + | - | + |
| African–American | + | + | ? |
| Tumour factors | |||
| Stage | TNM | TNM | Lymphatic involvement? |
| Histology score | Elston–Ellis | Gleason score | LAM histology score |
| Lymphovascular involvement | + | + | + |
| Receptor status | ER/PR/Her2 | - | ER/PR/Bcl2/TERT? |
| Circulating tumour cells | + | ? | + |
| Genetic profiling | + | - | ? |
| Serum marker of response to therapy | - | Decreased PSA | Decreased VEGF-D |
LAM: Lymphangioleiomyomatosis; TNM: tumour, nodes, metastasis; ER: oestrogen receptor; PR: progesterone receptor; Her2: Human epidermal growth factor receptor-2; Bcl2: B-cell lymphoma-2; TERT: telomerase reverse transcriptase; PSA: prostate specific antigen; VEGF-D: vascular endothelial growth factor-D; +: predictor associated with condition; -: predictor not associated with condition; ?: insufficient evidence regarding association.